Orginal Article |
|
|
|
|
Reserch Progress on Biomarkers and Precision Medicine |
Xi-wen JIANG(),Zi-wei DONG,Yue LIU,Xiao-ya ZHU |
Da An Gene Co.,Ltd. Of Sun yat-sen University, Guanzhou 510665, China |
|
|
Abstract Since the concept of precision medicine was proposed in 2015, more and more attention has been paid to biomarkers and precision medicine. Biomarkers is widely used in the screening and treatment of major diseases such as virus and cancer. The application and development of new circulating biomarkers have made great achievements in the development of HBV, HPV detection and tumor targeted drug therapy, cell therapy, immunosuppressant and cancer vaccine. Compared with traditional medical methods, biomarkers have significant advantages in both research and development and in the treatment of detection and treatment mode assisted by precision medicine. Therefore, this paper reviews the application of biomarkers and precision medicine, and focuses on the latest research progress of biomarkers and precision medicine in recent research reports.
|
Received: 10 January 2019
Published: 26 March 2019
|
|
|
|
[1] |
Collins F S, Varmus H . A New Initiative on Precision Medicine. N Engl J Med, 2015,372(9):793-795.
doi: 10.1056/NEJMp1500523
pmid: 25635347
|
|
|
[2] |
Liu X Y, Fan H Y , Sui-Yan Y E, et al. Combined traditional and modern method detection in the diagnosis of TB laboratory value. Journal of Yanan University(Medical Science Edition), 2016,14(4):27-30.
|
|
|
[3] |
Ashley E A . The precision medicine initiative: A new national effort. JAMA, 2015,313(21):2119-2120.
doi: 10.1001/jama.2015.3595
|
|
|
[4] |
Ptolemy A S, Rifai N . What is a biomarker? Research investments and lack of clinical integration necessitate a review of biomarker terminology and validation schema. Scandinavian Journal of Clinical and Laboratory Investigation, 2010,70(sup242):9.
doi: 10.3109/00365513.2010.493354
pmid: 20515269
|
|
|
[5] |
Tan L M, Long T T, Guan X L , et al. Diagnostic value of vitamin D status and bone turnover markers in rheumatoid arthritis complicated by osteoporosis. Annals of Clinical & Laboratory Science, 2018,48(2):197-204.
pmid: 29678847
|
|
|
[6] |
Rykova E Y, Morozkin E S, Ponomaryova A A , et al. Cell-free and cell-bound circulating nucleic acid complexes: mechanisms of generation, concentration and content. Expert Opinion on Biological Therapy, 2012,12(S1):S141-S153.
doi: 10.1517/14712598.2012.673577
pmid: 22500614
|
|
|
[7] |
Dawson S J, Rosenfeld N, Caldas C , et al. Circulating tumor DNA to monitor metastatic breast cancer. New England Journal of Medicine, 2013,368(13):1199-1209.
doi: 10.1056/NEJMoa1213261
pmid: 23822788
|
|
|
[8] |
Wan Jonathan C M, Massie C, Javier G C , et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nature Reviews Cancer, 2017,17(4):223.
doi: 10.1038/nrc.2017.7
pmid: 28233803
|
|
|
[9] |
Plaks V, Koopman C D , Werb Z. Circulating Tumor Cells. Science, 2013,341(6151):1186-1188.
doi: 10.1126/science.1235226
|
|
|
[10] |
Uyen-Thao L, Peter B, Francesco P , et al. Intraoperative detection of circulating tumor cells in pulmonary venous blood during metastasectomy for colorectal lung metastases. Scientific Reports, 2018,8(1):8751.
doi: 10.1038/s41598-018-26410-8
pmid: 29884810
|
|
|
[11] |
Tong B, Xu Y, Zhao J , et al. Prognostic significance of circulating tumor cells in non-small cell lung cancer patients undergoing chemotherapy. Oncotarget, 2017,8(49):86615-86624.
doi: 10.18632/oncotarget.21255
pmid: 5689711
|
|
|
[12] |
Yu M, Bardia A, Aceto N , et al. Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. Science, 2014,345(6193).
doi: 10.1126/science.1253533
pmid: 25013076
|
|
|
[13] |
Pan B T, Johnstone R M . Fate of the transferrin receptor during maturation of sheep reticulocytes in vitro: selective externalization of the receptor. Cell, 1983,33(3):967-978.
doi: 10.1016/0092-8674(83)90040-5
pmid: 6307529
|
|
|
[14] |
Johnstone R M . Revisiting the road to the discovery of exosomes. Blood Cells Molecules & Diseases, 2005,34(3):214-219.
doi: 10.1016/j.bcmd.2005.03.002
pmid: 15885604
|
|
|
[15] |
Pan B T, Teng K, Wu C , et al. Electron microscopic evidence for externalization of the transferrin receptor in vesicular form in sheep reticulocytes. Journal of Cell Biology, 1985,101(3):942-948.
doi: 10.1083/jcb.101.3.942
pmid: 2113705
|
|
|
[16] |
Johnstone R M . Exosomes biological significance: A concise review. Blood Cells, Molecules, and Diseases, 2006,36(2):315-321.
|
|
|
[17] |
Gang C, Huang A C, Wei Z , et al. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature, 2018,560:382-386.
doi: 10.1038/s41586-018-0392-8
|
|
|
[18] |
Haderk F, Schulz R, Iskar M , et al. Tumor-derived exosomes modulate PD-L1 expression in monocytes. Sci Immunol, 2017, 2(13):eaah5509.
|
|
|
[19] |
Kirschfink M, Terness P . Immunoblotting. Methods Mol Med, 1997,13(6):361-371.
|
|
|
[20] |
Engvall E . Enzyme immunoassay ELISA and EMIT. Methods Enzymol, 1980,70(A):419-439.
doi: 10.1016/S0076-6879(80)70067-8
|
|
|
[21] |
Famulok M . Oligonucleotide aptamers that recognize small molecules. Curr Opin Struct Biol, 1999,9(3):324-329.
doi: 10.1016/S0959-440X(99)80043-8
|
|
|
[22] |
Kwok P Y . SNP genotyping with fluorescence polarization detection. Human Mutation, 2002,19(4):315-323.
doi: 10.1002/humu.10058
pmid: 11933186
|
|
|
[23] |
Ronaghi M . Pyrosequencing sheds light on DNA sequencing. Genome Research, 2001,11(1):3-11.
doi: 10.1101/gr.11.1.3
pmid: 11156611
|
|
|
[24] |
Ferguson J A, Steemers F J, Walt D R . High-density fiber-optic DNA random microsphere array. Analytical Chemistry, 2000,72(22):5618-5624.
doi: 10.1021/ac0008284
pmid: 11101240
|
|
|
[25] |
Hindson C M, Chevillet J R, Briggs H A , et al. Absolute quantification by droplet digital PCR versus analog real-time PCR. Nature Methods, 2013,10(10):1003.
doi: 10.1038/nmeth.2633
pmid: 23995387
|
|
|
[26] |
Butler E K, Gersch J, Mcnamara A , et al. HBV serum DNA and RNA levels in nucleos(t)ide analogue‐treated or untreated patients during chronic and acute infection. Hepatology, 2018,68(6):2106-2117.
doi: 10.1002/hep.30082
pmid: 29734472
|
|
|
[27] |
Halgand B, Desterke C , Rivière, Lise, et al. Hepatitis B virus pregenomic RNA in hepatocellular carcinoma: A nosological and prognostic determinant. Hepatology, 2017,67(1):86-96.
doi: 10.1002/hep.29463
pmid: 28802063
|
|
|
[28] |
DNAArbyn M, Paraskevaidis E, Martin-Hirsch P , et al. Clinical utility of HPV-DNA detection: Triage of minor cervical lesions, follow-up of women treated for high-grade CIN: An update of pooled evidence. Gynecologic Oncology, 2005,99(3 suppl):S7-S11.
doi: 10.1016/j.ygyno.2005.07.033
pmid: 16154623
|
|
|
[29] |
Liao M Y, Huang Y . Analysis of vaginoscopy and HPV-DNA detection results of patients diagnosed with cervical atypical squamous cells. Maternal & Child Health Care of China, 2011,26(15):2274-2276.
|
|
|
[30] |
Wentzensen N, Vinokurova S , Magnus V K D. Systematic review of genomic integration sites of human papillomavirus genomes in epithelial dysplasia and invasive cancer of the female lower genital tract. Cancer Research, 2004,64(11):3878-3884.
doi: 10.1158/0008-5472.CAN-04-0009
|
|
|
[31] |
Ren C, Zhu Y, Yang L , et al. Diagnostic performance of HPV E6/E7 mRNA assay for detection of cervical high-grade intraepithelial neoplasia and cancer among women with ASCUS Papanicolaou smears. Archives of Gynecology & Obstetrics, 2018,297(2):425-432.
doi: 10.1007/s00404-017-4588-1
pmid: 29143102
|
|
|
[32] |
Mok T S, Wu Y L, Thongprasert S , et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. The Journal of Evidence-Based Medicine, 2009,361(10):947.
|
|
|
[33] |
Tey S K, Bollard C M, Heslop H E . Adoptive T-cell transfer in cancer immunotherapy. Immunology and Cell Biology, 2006,84(3):281-289.
doi: 10.1111/j.1440-1711.2006.01441.x
pmid: 16681825
|
|
|
[34] |
Ramos C A, Heslop H E, Brenner M K . CAR-T cell therapy for lymphoma. Annual Review of Medicine, 2016,67(1):165.
doi: 10.1146/annurev-med-051914-021702
pmid: 4732525
|
|
|
[35] |
Gross G, Waks T, Eshhar Z . Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci USA, 1989,86(24):10024-10028.
doi: 10.1073/pnas.86.24.10024
|
|
|
[36] |
Eshhar Z, Waks T, Gross G , et al. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proceedings of the National Academy of Sciences of the United States of America, 1993,90(2):720-724.
doi: 10.1073/pnas.90.2.720
|
|
|
[37] |
Brocker T . Chimeric Fv-ζ or Fv-ε receptors are not sufficient to induce activation or cytokine production in peripheral T cells. Blood, 2000,96(5):1999-2001.
doi: 10.1097/01.NNR.0000280661.34502.c1
pmid: 10961908
|
|
|
[38] |
Finney H M, Lawson A D, Bebbington C R , et al. Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product. Journal of Immunology, 1998,161(6):2791-2797.
pmid: 9743337
|
|
|
[39] |
Gianpietro D, Barbara S, Malcolm B . Fifteen years of gene therapy based on chimeric antigen receptors: “Are we nearly there yet? ” Human Gene Therapy, 2009,20(11):1229-1239.
doi: 10.1089/hum.2009.142
pmid: 19702437
|
|
|
[40] |
Marin V, Pizzitola I, Agostoni V , et al. Cytokine-induced killer cells for cell therapy of acute myeloid leukemia: improvement of their immune activity by expression of CD33-specific chimeric receptors. Haematologica, 2010,95(12):2144.
doi: 10.3324/haematol.2010.026310
pmid: 20713459
|
|
|
[41] |
Chmielewski M, Abken H . TRUCKs: the fourth generation of CARs. Expert Opinion on Biological Therapy, 2015,15(8):1145.
doi: 10.1517/14712598.2015.1046430
pmid: 25985798
|
|
|
[42] |
Lim W A , June C H. the principles of engineering immune cells to treat cancer. Cell, 2017,168(4):724.
doi: 10.1016/j.cell.2017.01.016
pmid: 28187291
|
|
|
[43] |
Zamai L, Zotto G D, Buccella F , et al. Cytotoxic functions and susceptibility to apoptosis of human CD56bright NK cells differentiated in vitro from CD34 + hematopoietic progenitors . Cytometry Part A, 2012,81A(4):294-302.
doi: 10.1002/cyto.a.22025
pmid: 22319021
|
|
|
[44] |
Frey M, Packianathan N B, Fehniger T A , et al. Differential expression and function of L-selectin on CD56bright and CD56dim natural killer cell subsets. Journal of Immunology, 1998,161(1):400-408.
pmid: 9647249
|
|
|
[45] |
Tang X, Yang L, Li Z , et al. First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia. American Journal of Cancer Research, 2018,8(6):1083.
pmid: 30034945
|
|
|
[46] |
Oates J, Jakobsen B K . ImmTACs. OncoImmunology, 2013,2(2):e22891.
doi: 10.4161/onci.22891
|
|
|
[47] |
Sharma P, Allison J P . The future of immune checkpoint therapy. Science, 2015,348(6230):56.
doi: 10.1126/science.aaa8172
|
|
|
[48] |
Jin X, Mu P . Targeting breast cancer metastasis. Breast Cancer: Basic and Clinical Research, 2015: 23.
|
|
|
[49] |
Le D T, Durham J N, Smith K N , et al. Mismatch-repair deficiency predicts response of solid tumors to PD-1 blockade. Science, 2017,357(6349):409.
doi: 10.1126/science.aan6733
pmid: 5576142
|
|
|
[50] |
Gandara D R, Paul S M, Marcin K , et al. Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab. Nature Medicine, 2018.
doi: 10.1038/s41591-018-0134-3
|
|
|
[51] |
Zachary R C, Caitlin F C, David F , et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Medicine, 2017,9:34.
doi: 10.1186/s13073-017-0424-2
pmid: 5395719
|
|
|
[52] |
Biswas A . Human papillomavirus (HPV) and cervical cancer. Journal of the Indian Medical Association, 2000,98(2):53-55.
doi: 10.2217/14750708.5.3.273
pmid: 11016151
|
|
|
[53] |
Kyrgiou M, Shafi M I . HPV vaccine. Obstetrics Gynaecology & Reproductive Medicine, 2009,19(1):26-28.
|
|
|
[54] |
Plosker G L. Sipuleucel-T . Drugs, 2011,71(1):101-108.
doi: 10.2165/11206840-000000000-00000
|
|
|
[55] |
Patrick A O, Hu Z T, Keskin D B , et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature, 2017,547(7662):217-221.
doi: 10.1038/nature22991
|
|
|
[56] |
Sahin U, Derhovanessian E, Miller M , et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature, 2017,547(7662):222-226.
doi: 10.1038/nature23003
|
|
|
[57] |
Sagiv-Barfi I, Czerwinski D K, Levy S , et al. Eradication of spontaneous malignancy by local immunotherapy. Science Translational Medicine, 2018, 10(426):eaan4488.
doi: 10.1126/scitranslmed.aan4488
pmid: 29386357
|
|
|
[58] |
Andrieu G P, Denis G V . BET proteins exhibit transcriptional and functional opposition in the epithelial-to-mesenchymal transition. Molecular Cancer Research, 2018,16(4):580-586.
doi: 10.1158/1541-7786.MCR-17-0568
|
|
|
[59] |
Mcnair C, Xu K, Mandigo A C , et al. Differential impact of RB status on E2F1 reprogramming in human cancer. Journal of Clinical Investigation, 2018,128(1):341.
doi: 10.1172/JCI93566
pmid: 29202480
|
|
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|